Lisocabtagene Maraleucel对比标准治疗用于二线复发/难治性大B细胞淋巴瘤:随机III期TRANSFORM研究的3年随访
TRANSFORM研究3年随访比较liso-cel与标准治疗用于二线原发难治/早期复发(≤12个月)大B细胞淋巴瘤。中位随访33.9个月,liso-cel组中位无事件生存期29.5个月 vs 标准治疗组2.4个月(HR 0.375),中位无进展生存期未达到 vs 6.2个月(HR 0.422),36个月总生存率63% vs 52%。
要点
- liso-cel组中位无事件生存期29.5个月,标准治疗组2.4个月(HR 0.375;95%CI 0.259-0.542)。
- liso-cel组中位无进展生存期未达到,标准治疗组6.2个月(HR 0.422;95%CI 0.279-0.639)。
- 36个月总生存率liso-cel组63% vs 标准治疗组52%,总生存HR 0.757(95%CI 0.481-1.191)。
核心结论
- 3年随访时,liso-cel对比标准治疗证实了更优且更持久的疗效,安全性特征良好且无新安全性信号。
- 这些数据支持liso-cel作为复发/难治性大B细胞淋巴瘤具有治愈潜力的有效二线治疗。
研究设计与样本
- 随机III期TRANSFORM研究,比较liso-cel与标准治疗用于二线原发难治/早期复发(≤12个月)大B细胞淋巴瘤。
- 符合自体干细胞移植条件的成人(N=184)按1:1随机分配至liso-cel(100×10^6嵌合抗原受体阳性T细胞)或标准治疗。
- 结果以描述性方式报告。
主要发现
- 中位随访33.9个月,liso-cel组中位无事件生存期29.5个月(95%CI 9.5至未达到),标准治疗组2.4个月(95%CI 2.2至4.9),HR 0.375(95%CI 0.259至0.542)。
- liso-cel组中位无进展生存期未达到(95%CI 12.6至未达到),标准治疗组6.2个月(95%CI 4.3至8.6),HR 0.422(95%CI 0.279至0.639),36个月无进展生存率分别为51% vs 26.5%。
- 两组中位总生存期均未达到(HR 0.757;95%CI 0.481至1.191),66%的患者交叉接受liso-cel治疗;36个月总生存率liso-cel组63% vs 标准治疗组52%。
- 校正交叉治疗效应后,总生存HR为0.566(95%CI 0.359至0.895), favoring liso-cel。
- 安全性结果与既往报告一致。
临床怎么用
- 原文结论支持liso-cel作为复发/难治性大B细胞淋巴瘤具有治愈潜力的有效二线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line primary refractory/early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (N = 184) were randomly assigned 1:1 to liso-cel (100 × 106 chimeric antigen receptor-positive T cells) or SOC. Results are reported descriptively. With a median follow-up of 33.9 months, median (95% CI) event-free survival was 29.5 months (9.5 to not reached [NR]) for liso-cel versus 2.4 months (2.2 to 4.9) for SOC (hazard ratio [HR], 0.375; 95% CI, 0.259 to 0.542). Median progression-free survival was NR (12.6-NR) for liso-cel versus 6.2 months (4.3-8.6) for SOC (HR, 0.422; 95% CI, 0.279 to 0.639) with 36-month rates of 51% versus 26.5%. Median overall survival (OS) was NR for both arms (HR, 0.757; 95% CI, 0.481 to 1.191), with 66% of patients crossing over to receive liso-cel; 36-month OS rate was 63% for liso-cel versus 52% for SOC. OS HR (0.566 [95% CI, 0.359 to 0.895]) favored liso-cel when accounting for the treatment effect of crossover. Safety results were consistent with previous reports. At 3-year follow-up, liso-cel confirmed superior, more durable efficacy versus SOC with a favorable safety profile and no new safety signals. These data support liso-cel as an effective second-line treatment with curative potential for relapsed/refractory LBCL.
引用
- Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. J Clin Oncol. 2025. PMID: 40623279. doi:10.1200/JCO-25-00399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。